World EPA Congress, 2024
— Richard Sear & Emilie Dubernay
Related articles
Why orphan medicines remain out of reach in low- and middle-income countries – and what can be done
Rare Diseases27/02/2026
Rare disease policy in high-income countries: An overview of achievements, challenges, and solutions
European PolicyRare DiseasesUS Policy10/05/2025
From launch to legacy: Pricing excellence through forecasting & analytics
Pricing05/03/2025
What do the new Medicare negotiations mean for pipeline orphan therapies?
Rare DiseasesUS Policy04/03/2025